Ropes & Gray Represents Alexion Pharmaceuticals, Inc. in Acquisition of Wilson Therapeutics
Ropes & Gray represented Alexion Pharmaceuticals, Inc., a global biopharmaceutical company focused on serving patients and families affected by rare diseases, in its acquisition of all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. The total equity value of the transaction amounts to approximately $855 million. The transaction was announced on April 11, 2018 and is expected to close in the second quarter of 2018, subject to customary closing conditions.
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ product, WTX101, is in Phase 3 development as a treatment for Wilson disease.
Ropes & Gray acted as U.S. legal advisor. The team is being led by securities & public companies partner Zachary Blume, antitrust counsel Deidre Johnson and associates Stephen Hall, Michael Sweeney and Derek Yee.